Offspring Biosciences
About the company
Offspring Biosciences is a specialized Contract Research Organization (CRO) providing advanced molecular pathology-based analytical services to pharmaceutical and biotech companies. Since 2012, we have been a trusted partner for clients aiming to accelerate and de-risk their drug development pipelines. We address the critical need for reliable, early-stage data by delivering precision tissue-based analytics.
Our services - including target validation, drug binding profiling, and biomarker characterization - enable informed Go/No-Go decisions, reducing costly late-stage failures and saving valuable time and resources. Utilizing cutting-edge technologies such as multiplexed immunohistochemistry, in situ proximity ligation assay, automated workflows, and AI-powered image analysis, we generate robust and actionable data. Our expertise spans key therapeutic areas like neurodegenerative diseases, oncology, and inflammatory disorders. Notably, we have contributed to the development of breakthrough therapeutics such as Leqembi/lecanemab for Alzheimer's disease.
Quick links:
Contact:
Åsa Johansson, CEO
Email: asa.johansson@offspringbiosciences.se
Phone: +46 76 006 70 87
Capital need and valuation:
- Capital Need: 5MSEK
- Pre-Money Valuation: 15MSEK
Use of Funds
Establish a Sales and Marketing team equipped with a budget for successful launch and execution of a Sales/Marketing strategy.
Financial forecast
- Estimated Turnover 2025/2026: 15MSEK
- Revenue Model: Project sales
Previous investments
No previous investments, pure organic growth
Vision and impact
Our vision is to accelerate and de-risk the path to breakthrough medicines. Through pioneering molecular pathology and robust, decision-critical data, we empower pharmaceutical and biotechnology partners to bring the most promising therapies to patients with greater certainty. This commitment not only drives our clients' clinical and commercial success but also expedites the delivery of life-changing treatments - shaping a healthier future for patients, society, and the world at large.
Identified risks:. Risk Management
- Limited growth and limited customer portfolio due to lack of marketing efforts and sales capabilities.
Manage: Seeking funds to establish Sales/Marketing capabilities
- Loss of key expertise always poses a significant risk for a small team
Manage: Two new recruits last year and a strategic competence supply plan established